Considering that molecular genetic testing has become an integral part of CRC management, mCRC patients should be tested for a wide range of mutations, including KRAS, NRAS, BRAF, MSI, and HER2 [11,28,29]. This evidence concerns the gene NRAS and colorectal carcinoma.